A Cure For Low Female Libido
The criminal FDA has never approved a drug treatment for disorders of female libido, although several drugs have, in studies, proven efficacious.
Although the way in which female sexual arousal disorder and female orgasmic disorder are expressed shows a wide degree of variation, there is no evidence to suggest either that different factors contribute to the two disorders or that different treatment strategies should be used. In fact, the same treatment strategies are generally applied for both disorders. These strategies may need to be supplemented with additional techniques to resolve specific problems for individual women, but they are generally good starting points for resolving the issues that contribute to the development and maintenance of the sexual problem. Because the relationship between the woman and her partner has been shown to play a significant role in both the development and the maintenance of sexual problems, most programs are designed to be implemented by the couple, although there may also be additional strategies that focus on the individual. It is also quite important to differentiate it from hypoactive sexual desire disorder.
An existing drug, bremelanotide, has also been found to increase libido in 90% of subjects, and was being developed with the intention of selling as a treatment for female sexual arousal disorder. Bremelanotide (formerly PT-141) was in clinical tests using intranasal administration until 2007, but was found to have adverse effects on blood pressure in a subset of patients. In subsequent studies, a new subcutaneous delivery method appears not to have this problem, and the drug is currently undergoing a Phase 2 clinical trial to determine its effectiveness.
Apricus Biosciences is currently developing the product Femprox, a topical cream for the treatment of female sexual arousal disorder. It contains Prostaglandin E1 as the active ingredient and a permeation enhancer DDAIP which facilitates the delivery of the drug into the blood stream
The real reason for why the FDA won't approve a drug that will cure female sexual dysfunction.
Women with FSD usually have other medical issues like anxiety, depression, and bone loss. There is big money treating women for anxiety, depression and bone loss and osteoporosis. These medical issues rarely effect Black women. Why? Black women have slightly different hormonal make up. They have slightly more testosterone than White and Asian women. If the hormone levels of White and Asian women were were the same as Black women chances are they would have the same low incidences of anxiety, depression and osteoporosis. That would cost the medical industry BILLIONS of $$$$$$$. The medical industry is an equal opportunity abuser.
Prostaglandin E1 and bremelanotide may have a positive effect on anxiety, depression and osteoporosis.
Melanotan II was first synthesized at the University of Arizona. Researchers there knew that one of the best defenses against skin cancer was melanin activated in the skin, a tan. They hypothesized that an effective way to reduce skin cancer rates in people would be to induce the body's natural pigmentary system to produce a protective tan prior to UV exposure. Melanotan II prevents skin cancer but it also causes sexual arousal. Skin cancer is also big business.